Cationic cyclopentadienyl mixed bis-N-heterocyclic carbene (NHC) nickel complexes of the general formula [Ni(NHC)(NHC′)Cp](PF 6 ) (NHC/NHC′ = 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene (Mes 2 NHC) a, 1,3-dimethylimidazol-2-ylidene (Me 2 NHC) b, 1-isopropyl-3-methyl-imidazol-2-ylidene ( i Pr-NHC-Me) c; Cp = η 5 -C 5 H 5 ) were prepared by the reaction of the cationic monocarbene complex [Ni(Mes 2 NHC)(NCMe)Cp](PF 6 ) 1a or [Ni(Me 2 NHC)(NCMe)Cp](BF 4 ) 1b with the appropriate free carbene. The new mixed bis(carbene) complexes [Ni(Mes 2 NHC)(Me 2 NHC)Cp](PF 6 ) 2ab, [Ni(Mes 2 NHC)( i Pr-NHC-Me)Cp](PF 6 ) 2ac, and [Ni(Me 2 NHC)( i Pr-NHC-Me)Cp](BF 4 ) 2bc were obtained in moderate-to-high yields and were fully characterized by 1 H and 13 C NMR spectroscopies, elemental analyses, and, in the case of 2ab, by a single-crystal X-ray diffraction study. The monocarbene precursor 1b was also structurally characterized. The mixed bis-NHC complexes 2ab and 2ac were tested as catalysts for the Suzuki–Miyaura cross-coupling of phenylboronic acid with 4′-bromoacetophenone, and their activities were compared to that of related monocarbene CpNi complexes.
No takes yet. Share an insight, caveat, or question.
Oertel et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: